Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

BofA Downgrades Forest Labs

Banc of America downgrades generic drug-maker Forest Labs (FRX) to sell from neutral.

Analyst David Maris says he is downgrading Forest Labs due to risks tied to the upcoming Lexapro trial and the earlier-than-expected entrance of generic drug Celexa. Based on his initial analysis of the upcoming May 2005 Lexapro trial with Ivax Corp., he believes there's credible risk to Lexapro.

Maris assigns a 25% chance for trial loss, which leads him to cut his $45 target to $34. He says, with Forest Lab stock trading near its peer multiple of 16 times 2005 estimates, he believes the market has only begun to consider risk to Lexapro. He adds that, without Lexapro, he estimates that Forest Labs shares may be worth $11.45.

blog comments powered by Disqus